Metabolic effect of telmisartan and losartan in peritoneal dialysis patients

Metabolic effect of telmisartan and losartan in peritoneal dialysis patients - Metabolic effect of telmisartan and losartan in peritoneal dialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000383

Enrollment

Registered

2006-03-31

Start date

2006-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal dialysis patients

Interventions

losartan(25mg or 50mg twice a day) for 3 months,then telmisartan(20mg or 40 mg twice a day)for 3 months,then losartan(25mg or 50mg twice a day) for 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: non-diabetic peritoneal dialysis patients

Exclusion criteria

Exclusion criteria: 1)morning blood pressure 6.0 mEq/l)

Design outcomes

Primary

Measure	Time frame
effect on lipid profile and insulin sensitivity;waist,BMI,T-Cho,TG,LDL-C,leptin,HOMA-IR,values of glucose and insulin in the oral glucose tolerance test	—

Secondary

Measure	Time frame
1)effect on inflammation;serum hsCRP,IL- 6,TNFarfa 2)effect on blood pressure;ambulatory blood pressure monitoring 3)effect on residual renal function; renal Ccr,urine protein	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026